dc.contributor.author | Smyth, G | |
dc.contributor.author | Mowat, S | |
dc.contributor.author | Chia, K | |
dc.contributor.author | Robinson, K | |
dc.contributor.author | Warren-Oseni, K | |
dc.contributor.author | Welsh, LC | |
dc.contributor.author | Blasiak-Wal, I | |
dc.contributor.author | Mandeville, HC | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-09-05T11:43:08Z | |
dc.date.available | 2022-09-05T11:43:08Z | |
dc.date.issued | 2022-04-01 | |
dc.identifier | S0936-6555(22)00020-6 | |
dc.identifier.citation | Clinical Oncology, 2022, 34 (4), pp. 211 - 219 | en_US |
dc.identifier.issn | 0936-6555 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5407 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.doi | 10.1016/j.clon.2022.01.004 | |
dc.description.abstract | AIMS: To determine if multi-isocentric volumetric modulated arc radiotherapy for craniospinal irradiation (CSI-VMAT) can be implemented safely and accurately using robust optimisation in a commercially available treatment planning system. Our initial clinical experience is reported for the first 20 patients treated with the technique. MATERIALS AND METHODS: Patients received between 23.4 and 39.6 Gy (mode 23.4 Gy) in 13-22 fractions with CSI-VMAT. The heart mean dose was 4.2-10.3 Gy (median 5.3 Gy) for patients prescribed up to 24 Gy and 6.5-16.3 Gy (median 10.1 Gy) for patients receiving 35 Gy or more. The lung mean dose was 5.5-7.6 Gy (median 6.8 Gy) for patients prescribed up to 24 Gy and 6.9-11.1 Gy (median 10.0 Gy) for patients receiving 35 Gy or more. The robustness of the planning target volume D0.1cm3 and D99% to systematic errors in the isocentre superoinferior position of up to 5 mm was evaluated. These remained acceptable but were correlated to the length of the available beam overlap through the neck. RESULTS: As of January 2021, one patient was deceased after 508 days and one patient was lost to follow-up after completing treatment. The median follow-up was 399 days (range 175-756 days) and progression-free survival was 131 days (34-490 days). Acute toxicities at Common Terminology Criteria for Adverse Events v5.0 grade 3+ included lowered white blood cell count (16/20), decreased platelet count (8/20), nausea (5/20), vomiting (2/20), pharyngeal mucositis (1/20) and oral mucositis (1/20). Three patients developed grade 4 neutropenia or decreased white blood cell count. CONCLUSIONS: CSI-VMAT can be implemented safely and accurately using robust optimisation functions in a commercially available treatment planning system. | |
dc.format | Print-Electronic | |
dc.format.extent | 211 - 219 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | ELSEVIER SCIENCE LONDON | en_US |
dc.relation.ispartof | Clinical Oncology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Craniospinal irradiation | |
dc.subject | multi-isocentric | |
dc.subject | robustness | |
dc.subject | volumetric modulated arc therapy | |
dc.subject | Craniospinal Irradiation | |
dc.subject | Heart | |
dc.subject | Humans | |
dc.subject | Organs at Risk | |
dc.subject | Radiotherapy Dosage | |
dc.subject | Radiotherapy Planning, Computer-Assisted | |
dc.subject | Radiotherapy, Intensity-Modulated | |
dc.title | Clinical Implementation of Robust Multi-isocentric Volumetric Modulated Arc Radiotherapy for Craniospinal Irradiation. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-01-04 | |
dc.date.updated | 2022-09-05T11:42:31Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.clon.2022.01.004 | en_US |
rioxxterms.licenseref.startdate | 2022-04-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35063327 | |
pubs.issue | 4 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Paediatric and Adolescent Radiotherapy | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.clon.2022.01.004 | |
pubs.volume | 34 | |
icr.researchteam | Paed & Adolesc Radiother | en_US |
dc.contributor.icrauthor | Smyth, Gregory | |
dc.contributor.icrauthor | Mandeville, Henry | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-05. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0936655522000206-main.pdf | |